Drug Trial Radar · NCT07137585
A Study to Evaluate the Effect of RO7204239 on Insulin Sensitivity and Muscle Composition in Participants With Type 2 Diabetes Mellitus (T2DM) and Overweight or Obesity
Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Sep 30, 2025
Primary completion
Sep 14, 2026
Study completion Feb 28, 2027
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Aug 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to assess the effect of RO7204239 on insulin sensitivity versus placebo in participants with T2DM and obesity or overweight.
Conditions
- Type 2 Diabetes Mellitus
- Obesity
- Overweight
Interventions
PlaceboDrug
RO7204239 matching placebo will be administered as per the schedule specified in the treatment arm.
RO7204239Drug
RO7204239 will be administered as per the schedule specified in the treatment arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in M-value in a Hyperinsulinemic Euglycemic Glucose Clamp (HEC) at Week 24Time frame: Baseline, Week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Profil Institut für Stoffwechselforschung
Homburg, Saarland, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.